|1.||Gangjee, Aleem: 12 articles (09/2015 - 04/2002)|
|2.||Botta, Maurizio: 12 articles (05/2015 - 07/2002)|
|3.||Schenone, Silvia: 12 articles (05/2015 - 11/2004)|
|4.||Hou, Zhanjun: 7 articles (09/2015 - 10/2010)|
|5.||Matherly, Larry H: 7 articles (09/2015 - 10/2010)|
|6.||Da Settimo, Federico: 7 articles (11/2014 - 08/2007)|
|7.||La Motta, Concettina: 7 articles (11/2014 - 08/2007)|
|8.||Balzarini, Jan: 7 articles (07/2012 - 08/2005)|
|9.||Cherian, Christina: 5 articles (11/2013 - 10/2010)|
|10.||Liekens, Sandra: 5 articles (07/2012 - 12/2007)|
07/15/2008 - "hyorhinis with several human cancers, our findings suggest that pyrimidine nucleoside-based but not 5FU-based anti-cancer therapy might be more effective when combined with a mycoplasmal TP inhibitor."
08/04/2009 - "A study of pyrimidine base damage in relation to oxidative stress and cancer."
04/01/1992 - "[Pharmacokinetic studies on fluorinated pyrimidine in cancer cell and tissue]."
02/01/1992 - "While clinical studies have attempted to measure the halogenated pyrimidine incorporation, few have successfully related tumor response to the incorporation of IdUrd by the tumor. "
01/01/1984 - "New trials of the pyrimidine analogs against tumor which are surrounded by slowly or non-dividing normal tissue appear appropriate. "
04/15/2010 - "Key to this outcome was the switch from a pyridyl to pyrimidine at the C(4)-position leading to analogs that were potent in human whole blood based cell assay as well as in a number of animal efficacy models for rheumatoid arthritis. "
06/01/2004 - "Leflunomide, an oral pyrimidine synthesis inhibitor, is highly effective in the treatment of rheumatoid arthritis, and small studies have suggested similar efficacy in PsA. "
11/22/1999 - "Leflunomide is a reversible inhibitor of de novo pyrimidine synthesis shown to be effective in a phase 2 trial in 402 patients with active rheumatoid arthritis (RA). "
08/01/2003 - "The pyrimidine analog, leflunomide, has demonstrated efficacy in the treatment of rheumatoid arthritis (RA) patients. "
01/23/1999 - "Phase II trials of leflunomide, an inhibitor of de-novo pyrimidine synthesis, have shown efficacy in rheumatoid arthritis. "
01/01/2012 - "In the present study a series of novel Biginelli-type pyrimidine compounds were evaluated as potential anti-human immunodeficiency virus (HIV)-1 agents using green fluorescence protein (GFP) reporter single round HIV-1 infection assay. "
05/20/2015 - "We then focus on changes that pathogen infections cause in the pyrimidine metabolism of their host. "
04/01/2015 - "3,4-Dihydro-2H-benzo[4,5]isothiazolo[2,3-a]pyrimidine is a newly identified antiviral agent against human immunodeficiency virus type 1 (HIV-1) infection, derived from 3,4-dihydro-2H,6H-pyrimido[1,2-c][1,3]benzothiazin-6-imine (PD 404182). "
12/16/2014 - "We find that HCMV infection substantially induces de novo pyrimidine biosynthetic flux. "
03/10/2014 - "These findings suggest the importance of de novo pyrimidine biosynthesis during the fast replicative early infection stages and highlight the dynamics of the metabolism associated with the hemibiotrophic life style of pathogen."
12/01/2011 - "Pre-treatment of tissues with the AMPK inhibitor 6-[4-(2-piperidin-1-yl-ethoxy)-phenyl)]-3-pyridin-4-yl-pyyrazolo [1,5-a] pyrimidine (compound C) in part reversed the effects of acute hypoxia on chloride secretion. "
03/01/1998 - "Thus, pRB, a key member of the cell cycle checkpoint network, seems to play a major role by inducing growth arrest under moderate hypoxia, and it gradually overrides hypoxia-induced suppression of pyrimidine metabolism in the regulation of progression through S-phase under such conditions."
03/01/1998 - "However, NHIK 3025 cells, in which pRB is abrogated by expression of the HPV18 E7 oncoprotein, and SAOS-2 cells, which lack pRB expression, continued cell cycle progression under moderate hypoxia provided that excess pyrimidine deoxynucleosides were present. "
03/01/1998 - "The addition of pyrimidine deoxynucleosides did not release T-47D cells, containing mainly underphosphorylated pRB, from the cell cycle arrest induced by moderate hypoxia. "
10/01/2007 - "The aim of our study was to determine whether post-infection administration of de novo pyrimidine synthesis inhibitors could prevent the reduction in alveolar fluid clearance (AFC) and hypoxemia that occurs at Day 2 after intranasal infection of BALB/c mice with RSV. "
07/01/1996 - "In patients with metastatic carcinoma of the large bowel who had not been treated in the past with a fluorinated pyrimidine, 39% of patients had a partial or complete remission, with a mean duration of response of 16.5 months. "
01/01/2012 - "The mechanism of antiproliferative effect of 5-(2-chloroethyl)-substituted pyrimidine 3 that exerted the pronounced cytostatic activity was studied in further details on colon carcinoma (HCT116) cells. "
06/01/2009 - "We report a case of anaplastic carcinoma of the thyroid administered peroral fluorinated pyrimidine, providing longterm survival during three years. "
06/01/2009 - "[A case of anaplastic carcinoma of thyroid administered peroral fluorinated pyrimidine for long-term survival during three years]."
07/01/1993 - "Pathological features and pyrimidine nucleotide synthesis in human gastric carcinomas."
|7.||DNA (Deoxyribonucleic Acid)
|9.||RNA (Ribonucleic Acid)
|2.||Drug Therapy (Chemotherapy)